32 min listen
RTL 02 -- The latest news from MDedge Hematology/Oncology: MRI IDs significant prostate cancer, drug interactions to avoid in GI cancers, ctDNA cleara…
FromBlood & Cancer
RTL 02 -- The latest news from MDedge Hematology/Oncology: MRI IDs significant prostate cancer, drug interactions to avoid in GI cancers, ctDNA cleara…
FromBlood & Cancer
ratings:
Length:
13 minutes
Released:
Jul 21, 2020
Format:
Podcast episode
Description
The latest news from MDedge Hematology/Oncology: In this episode: MRI reliably identifies significant prostate cancer * Original MDedge article (https://bit.ly/3hgKT1h) * PROMIS analysis (https://bit.ly/3fLOiEN) Drug-drug interactions to avoid in patients with GI cancer * Original MDedge article (https://bit.ly/39eHi0G) ctDNA clearance tracks with PFS in NSCLC subtype * Original MDedge article (https://bit.ly/3eJKm6o) * Abstract from AACR 2020 (https://bit.ly/30uQQ3R) * TATTON results in The Lancet Oncology (https://bit.ly/3jq1L7J) COVID-19 symptoms can linger for months * Original MDedge article (https://bit.ly/3eNREG0) * JAMA research letter (https://bit.ly/2WFS3UW) For more MDedge Podcasts go to https://mdedge.com/podcasts/ Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgeHemOnc
Released:
Jul 21, 2020
Format:
Podcast episode
Titles in the series (100)
Is this a good study? The statistics tell the story: Ever read through a study and wondered how to apply the hazard ratio, or if you should change your practice because of a secondary endpoint finding? In this episode, , of the University of Pennsylvania, Philadelphia, explains all the common terms and... by Blood & Cancer